{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:11:44Z","timestamp":1790615504811,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ygyno.2011.03.036","type":"journal-article","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T09:06:10Z","timestamp":1303290370000},"page":"111-115","source":"Crossref","is-referenced-by-count":98,"title":["A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study"],"prefix":"10.1016","volume":"122","author":[{"given":"Robert L.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Soper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Lentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.03.036_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. [comment]","volume":"334","author":"McGuire","year":"1996","journal-title":"New Eng J Med"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0010","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2008.19.2963","article-title":"Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group","volume":"27","author":"Miller","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","article-title":"Protein nanoparticles as drug carriers in clinical medicine","volume":"60","author":"Hawkins","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0030","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: a next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0035","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","article-title":"Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel","volume":"14","author":"Gardner","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0040","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CAD.0b013e32830f9046","article-title":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","volume":"19","author":"Desai","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0045","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1586\/14737140.7.7.919","article-title":"Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy","volume":"7","author":"Henderson","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10549-009-0424-z","article-title":"Nab-paclitaxel weekly or every 3weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial","volume":"119","author":"Dranitsaris","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1469-7793.2001.0547a.x","article-title":"Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung","volume":"533","author":"John","year":"2001","journal-title":"J Physiol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","article-title":"SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients","volume":"2","author":"Desai","year":"2009","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0065","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0070","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.2008.18.9548","article-title":"Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer","volume":"27","author":"Teneriello","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.5011","article-title":"A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer","volume":"28","author":"Benigno","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1081\/CNV-120023765","article-title":"Weekly paclitaxel infusion as salvage therapy in ovarian cancer","volume":"21","author":"Boruta","year":"2003","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1525-1438.2003.13045.x","article-title":"Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0090","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ygyno.2003.12.002","article-title":"The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer","volume":"92","author":"Kita","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0095","first-page":"37","article-title":"Weekly paclitaxel in the management of ovarian cancer","volume":"27","author":"Markman","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0100","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.ygyno.2011.03.036_bb0105","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S1040-8428(02)00103-8","article-title":"Role of weekly paclitaxel in the treatment of advanced ovarian cancer","volume":"44","author":"Thomas","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0110","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2010.01.040","article-title":"Assessment of tumor response as a surrogate endpoint of survival in recurrent\/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study","volume":"117","author":"Rose","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0115","first-page":"174","article-title":"Weekly paclitaxel in the treatment of recurrent ovarian carcinoma","volume":"28","author":"Byrd","year":"2007","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0120","first-page":"383","article-title":"A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients","volume":"23","author":"Kaern","year":"2002","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/02841860500417486","article-title":"On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A","volume":"45","author":"Albertsson","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0130","first-page":"1843","article-title":"The microtubule-affecting drug paclitaxel has antiangiogenic activity","volume":"2","author":"Belotti","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0135","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/mt.2010.34","article-title":"Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis","volume":"18","author":"Chen","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0140","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00280-005-0163-8","article-title":"The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin","volume":"58","author":"Damber","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0145","first-page":"1759","article-title":"Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy","volume":"24","author":"Drevs","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00280-003-0693-x","article-title":"Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line","volume":"53","author":"Hata","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0155","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1158\/1078-0432.CCR-05-0910","article-title":"Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model","volume":"11","author":"Hu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0160","first-page":"81","article-title":"Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol","volume":"57","author":"Klauber","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/cbr.1999.14.31","article-title":"Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer","volume":"14","author":"Lau","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0170","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/0008-5472.CAN-04-2624","article-title":"Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells","volume":"65","author":"Pasquier","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00001813-200301000-00003","article-title":"Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly","volume":"14","author":"Wang","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0180","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/00001813-200410000-00007","article-title":"Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?","volume":"15","author":"Lau","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/0008-5472.CAN-06-3282","article-title":"Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer","volume":"67","author":"Kamat","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.03.036_bb0190","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ygyno.2009.08.032","article-title":"Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer","volume":"115","author":"Hurt","year":"2009","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811002599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811002599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T01:24:32Z","timestamp":1560129872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811002599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0090825811002599"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.03.036","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}